Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Investors Punish CVS Health For Providing Tepid Forecast


CVS Health Corp (NYSE: CVS) delivered better than expected EPS for the third quarter though revenue missed. However, the company offered downbeat guidance for the fourth quarter and next year.

  • Reports 28 percent increase in adjusted EPS to $1.64, beats by $0.07.
  • Delivers 15.5 percent growth in revenue of $44.6 billion; misses by $0.69 billion.
  • Offers adjusted EPS forecast of $1.64-$1.70 for the fourth quarter versus $1.79 expectations.
  • Lowered and Narrowed full year adjusted EPS from $5.81-$5.89 to $5.77-$5.83 compared to $5.85 expected by the Street.
  • For the full year 2017, CVS expects adjusted EPS of $5.77-$5.93 versus $6.53 expected by analysts.
  • Announces a fresh share buyback program of a maximum of $15 billion.

CVS Health President and CEO Larry Merlo stated, "We are currently experiencing slowing prescription growth in the overall market as well as a soft seasonal business. These factors combined are leading us to reduce the mid-point of our guidance for this year by five cents per share. The network changes have more significant implications for our 2017 outlook. While we expect a healthy increase in PBM operating profit growth in 2017, we expect a decrease in retail operating profit growth."

The stock plunged 11.98 percent to $73.40 in the pre-market session.

Posted-In: Earnings News Guidance Movers


Related Articles (CVS)

View Comments and Join the Discussion!

10 Stocks That Rallied For Three Days On Increasing Volume, No News

Hertz Shares Tank 30% After Big Earnings Miss